GET DAILY SIGNALSWhy Is Legend Biotech Corporation (LEGN) Stock Down -6.55% Today?
Key Takeaways
- Legend Biotech (LEGN) shares fell 6.55% to $22.70 in Tuesday trading, down $1.59 from Monday's close of $24.29, after gapping as much as 15% lower at the open.
- Primary catalyst: third-quarter 2026 results published before the bell — revenue edged past consensus and adjusted earnings matched it, but the bottom line delivered no upside to investors who had bid the stock up sharply into the print.
- Secondary drivers: U.S. CARVYKTI net trade sales grew 19% year over year, a marked deceleration from earlier quarters, while license and other revenue slipped to $6.3 million from $10.6 million.
- Profit-taking amplified the move: the stock had climbed roughly 15% in the five sessions before the report and about 36% off its October 12 close.
- Broader context: sector benchmarks were only modestly lower — small-cap biotech and large-cap biotech ETFs each slipped less than 1% — so the sell-off was company-specific, with the Nasdaq off about 1%.
- News Significance Score: 42/100 — Moderate quarterly news and a move about 2.3 times the stock's typical daily swing.
- What traders are watching: the December 23 FDA decision on a rival BCMA CAR-T, LB2501 data at ASH, and whether fourth-quarter gross margin lands in the high-50% range management guided to.
- Dive deeper into LEGN's Price Targets, Earnings, and Forecast pages for the full fundamental picture behind today's move.
- Explore Trending AI Robots to see which automated strategies are currently performing best across thousands of tickers.
Opening Summary
Legend Biotech Corporation (LEGN) is a Bridgewater, New Jersey-based cell therapy company and the largest standalone CAR-T developer in the industry, best known for CARVYKTI, the one-time multiple myeloma treatment it commercializes with Johnson & Johnson (JNJ). Shares were trading at $22.70 on Tuesday, down 6.55% from the prior session's close of $24.29, confirming a decisive downward move. The trigger was the company's third-quarter 2026 report, released before the opening bell: total revenue of $359.5 million and adjusted earnings of $0.14 per share both landed essentially where analysts expected, leaving little room for a stock that had already rallied hard into the announcement.
Earnings Fail to Extend the Profitability Story
The quarter itself was not weak. Legend reported net income of $51.7 million, or $0.13 per diluted share, versus a net loss of $39.6 million a year earlier, and operating income of $46.8 million against a year-ago operating loss of $43.3 million. Collaboration revenue rose to $353.2 million from $261.8 million, and CARVYKTI net trade sales climbed 36% year over year to roughly $710 million.
But the market had already been paid for that growth. After Q2 delivered Legend's first-ever quarterly profit, expectations shifted from "can this company break even" to "how fast can the profit line compound." A quarter that matched consensus on adjusted earnings, rather than beating it, removed the surprise element. A $4.3 million decline in license and other revenue, tied to lower recognition from a prior Novartis licensing arrangement, added a small dent. The stock's 12% pre-market decline reflected that recalibration rather than any single line item.
U.S. Growth Is Slowing Even as the Global Story Improves
The detail that drew the most scrutiny was geography. CARVYKTI's international sales jumped 86% year over year, while U.S. net trade sales grew just 19%. International expansion is real — the therapy is now available at 373 treatment sites across 20 markets — but the fastest-growing regions carry heavier launch costs and thinner economics under the 50/50 Johnson & Johnson collaboration.
Management pushed back on the concern, noting that second- and third-line patients accounted for 50% of U.S. apheresis volume in the quarter, up from 41% in the first quarter and 29% a year earlier, supported by updated NCCN guidance favoring early referral to T-cell-capable centers. That shift is the core of the bull case. It is also the number investors will hold the company to, because earlier-line penetration is precisely what a rival fourth-line-plus entrant cannot take away.
A Crowded Run Into the Print
Positioning did much of the damage. LEGN closed at $17.80 on October 12 and at $24.29 on November 9 — a 36% rebound that included a 6.01% gain on November 4 and back-to-back advances of 3.82% and 3.80% on November 6 and 9. With the shares pressing the top of a month-long range and a competitive overhang unresolved, the earnings report became an exit door for short-term holders rather than an entry point.
The intraday pattern fits that interpretation. Shares opened at $21.33, touched $20.66 — nearly 15% below Monday's close — and then climbed steadily back toward $22.70 as longer-horizon buyers absorbed the gap. By mid-morning the stock had recovered roughly half its opening loss, a signature of selling driven by expectation reset rather than by a broken thesis.
Market Context and Trading Activity
Volume confirmed the significance. About 335,000 shares changed hands in the first fifteen minutes of Tuesday's session, close to a third of the stock's typical full-day turnover of roughly 1.1 million shares — an extremely heavy opening pace consistent with an earnings-day reset. The move was almost entirely idiosyncratic: the small-cap biotech ETF (XBI) eased 0.3%, the large-cap biotech ETF (IBB) slipped 0.7%, and Johnson & Johnson was fractionally lower, so none of the sector tape explains a decline of this size. Broader indices were softer but nowhere near this magnitude, with the Nasdaq down roughly 1%. Technically, the drop ended a five-session winning streak and retraced part of the October–November advance, leaving the shares above their recent base but below the levels that capped the stock in early autumn.
News Significance Score
On a scale where 0 means no meaningful news and a move entirely normal for the stock, and 100 means transformative news paired with a rare, extreme price move, LEGN scores 42 out of 100.
The news was material but not decisive: a quarterly report that cleared revenue expectations and produced a second consecutive quarter of profit, yet carried slower U.S. growth and a bottom line that merely matched consensus rather than beating it. Tuesday's decline was roughly 2.3 times the stock's average absolute daily move of about 2.8% across the past 60 sessions, and only one of those sessions produced a larger swing. Solid, mid-weight news combined with a moderately unusual move produces the mid-range score.
What Comes Next for LEGN
The next hard catalyst is the December 23 FDA decision date on Gilead Sciences' (GILD) anito-cel, a rival BCMA CAR-T expected to carry a fourth-line-plus label — the segment Legend estimates at roughly 59% of current U.S. CARVYKTI use. Before that, the American Society of Hematology meeting in December should bring updated LB2501 in vivo CAR-T data across three dose levels, a program that has generated 100% response rates at the middle dose in a small cohort and represents the company's second growth engine. Management has reaffirmed its expectation of company-wide profitability for full-year 2026 on an adjusted net income basis, with fourth-quarter gross margin guided to the high-50% range from 58% in Q3. Investors will also weigh the durability of earlier-line conversion, the mix shift toward outpatient settings and its effect on net pricing, cash burn against $853 million in cash and time deposits, and the risk that bispecific combinations from Johnson & Johnson erode CARVYKTI's position in earlier lines.
Trending AI Robots
Tickeron maintains hundreds of AI trading bots that cover thousands of tickers, and only the strongest performers under current market conditions are surfaced in its curated Trending AI Robots section. The bots differ widely by strategy, timeframe, performance metrics, and the symbols they trade, so the lineup shifts as volatility and leadership rotate across the market. For readers tracking swings like today's in LEGN, the page offers a practical way to compare live strategies side by side and identify approaches suited to current conditions — worth a look before the next session opens.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
LEGN in upward trend: 10-day moving average crossed above 50-day moving average on October 28, 2026
The 10-day moving average for LEGN crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
LEGN moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +7.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where LEGN advanced for three days, in 176 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Aroon Indicator entered an Uptrend today. In 106 of 133 cases where LEGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
Bearish Trend Analysis
The 10-day RSI Indicator for LEGN moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In 20 of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at 87%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 51 of 57 cases where LEGN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 89%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LEGN as a result. In 91 of 100 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LEGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
LEGN broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.701) is normal, around the industry mean (3.498). P/E Ratio (-46.800) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (2.478) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. LEGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 45 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LEGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a holding company which engages in the discovery and development of novel cell therapies for oncology and other indications
Industry Biotechnology
Advertisement